{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:28:58Z","timestamp":1793276938198,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100207","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:27:54Z","timestamp":1771262874000},"page":"100207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9390-5645","authenticated-orcid":false,"given":"Mohamed Nazem","family":"Alibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-639X","authenticated-orcid":false,"given":"Antonino","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1942","authenticated-orcid":false,"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3239","article-title":"Classic Hodgkin lymphoma","volume":"42","author":"Kahn","year":"2024","journal-title":"Hematol Oncol"},{"issue":"suppl 4","key":"10.1016\/j.bneo.2026.100207_bib2","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","article-title":"Nivolumab in the treatment of Hodgkin lymphoma","volume":"23","author":"Ansell","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.bneo.2026.100207_bib4","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2026.100207_bib5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+ AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bneo.2026.100207_bib6","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bneo.2026.100207_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical Hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib11","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.bneo.2026.100207_bib13","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib14","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","article-title":"Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis","volume":"25","author":"Meng","year":"2025","journal-title":"BMC cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.bneo.2026.100207_bib18","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bneo.2026.100207_bib19","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PPO.0000000000000164","article-title":"Checkpoint inhibition: programmed cell death 1 and programmed cell death 1 ligand inhibitors in Hodgkin lymphoma","volume":"22","author":"Villasboas","year":"2016","journal-title":"Cancer J"},{"issue":"27","key":"10.1016\/j.bneo.2026.100207_bib21","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.bneo.2026.100207_bib23","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib24","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100207_bib26","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1182\/blood-2025-7140","article-title":"Efficacy and safety of nivolumab-based therapies in first-line and relapsed\/refractory Hodgkin lymphoma","volume":"146","author":"Nasir","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100207_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104980","article-title":"Predictive models for immune checkpoint inhibitor response in cancer: a review of current approaches and future directions","volume":"216","author":"Oisakede","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100207_bib28","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1182\/blood-2022-158869","article-title":"Updated results and correlative analysis: autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial)","volume":"140","author":"Ahmed","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100207_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1067289","article-title":"Advances in the treatment of Hodgkin lymphoma: current and future approaches","volume":"13","author":"Ullah","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.bneo.2026.100207_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101931","article-title":"Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma","volume":"82","author":"Veldman","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib31","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2026.100207_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105679","article-title":"Clinical use of circulating tumor DNA analysis in patients with lymphoma","volume":"156","author":"Bisig","year":"2025","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54512-7","article-title":"Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma","volume":"15","author":"Paczkowska","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib34","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/biology12060862","article-title":"Unraveling the immune microenvironment in classic Hodgkin lymphoma: prognostic and therapeutic implications","volume":"12","author":"Georgoulis","year":"2023","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of Hodgkin lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.bneo.2026.100207_bib37","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2026.100207_bib38","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2026.100207_bib39","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bneo.2026.100207_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1515250","article-title":"Tumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults","volume":"15","author":"Aoki","year":"2025","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PPO.0000000000000334","article-title":"Novel biomarker approaches in classic Hodgkin lymphoma","volume":"24","author":"Aoki","year":"2018","journal-title":"Cancer J"},{"issue":"14","key":"10.1016\/j.bneo.2026.100207_bib43","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100207_bib44","article-title":"The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes","volume":"4","author":"Nagpal","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"10.1016\/j.bneo.2026.100207_bib46","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100207_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib48","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/ijms20102416","article-title":"Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it","volume":"20","author":"Aldinucci","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib49","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","article-title":"Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma","volume":"5","author":"Gholiha","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib50","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0394632016644447","article-title":"Role of mast cells in fibrosis of classical Hodgkin lymphoma","volume":"29","author":"Nakayama","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100207_bib52","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.bneo.2026.100207_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib55","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2026.100207_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1420920","article-title":"Immune checkpoint inhibitors targeting PD-1\/PD-L1 in the treatment of human lymphomas","volume":"14","author":"Ribatti","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100207_bib58","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"7338","key":"10.1016\/j.bneo.2026.100207_bib59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib60","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/ijms26125592","article-title":"High PD-L1 expression in HRS cells and macrophages in tumor immune microenvironment Is associated with adverse outcome and EBV positivity in classical Hodgkin lymphoma","volume":"26","author":"Miljak","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bneo.2026.100207_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1149616","article-title":"An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma","volume":"13","author":"Ferrarini","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib62","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression\u2013based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124531","article-title":"Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival","volume":"10","author":"Barros","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bneo.2026.100207_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.957208","article-title":"PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival","volume":"12","author":"Jimenez","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib65","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100207_bib66","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.12659\/MSM.896629","article-title":"Classical Hodgkin lymphoma with positive Epstein-Barr virus status is associated with more FOXP3 regulatory T cells","volume":"22","author":"Pavlovic","year":"2016","journal-title":"Med Sci Monit"},{"issue":"19","key":"10.1016\/j.bneo.2026.100207_bib67","first-page":"2343","article-title":"Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphoma","volume":"141","author":"Stewart","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bneo.2026.100207_bib68","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein\u2013Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bneo.2026.100207_bib69","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib70","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/cancers17091481","article-title":"Epstein\u2013Barr infection, Hodgkin\u2019s lymphoma, and the immune system: insights into the molecular mechanisms facilitating immune evasion","volume":"17","author":"Tsotridou","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.bneo.2026.100207_bib71","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.3390\/ijms20215503","article-title":"Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical Hodgkin lymphoma","volume":"20","author":"Calabretta","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101514","article-title":"Hodgkin lymphoma: a disease shaped by the tumor micro-and macroenvironment","volume":"36","author":"Masel","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100207_bib73","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib74","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"7996","key":"10.1016\/j.bneo.2026.100207_bib76","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bneo.2026.100207_bib77","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib78","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib79","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V87.9.3844.bloodjournal8793844","article-title":"Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and-negative Hodgkin's disease","volume":"87","author":"Oudejans","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib80","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V92.3.1020","article-title":"Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition","volume":"92","author":"Lee","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The role of T cells in the microenvironment of Hodgkin lymphoma","volume":"99","author":"Wein","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib82","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bneo.2026.100207_bib83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib84","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41375-020-0737-9","article-title":"PD-L1\/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma","volume":"34","author":"Kawashima","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.bneo.2026.100207_bib86","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib87","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib88","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V92.7.2252","article-title":"Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells","volume":"92","author":"Bosshart","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib89","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib90","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib91","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib92","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib93","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen\u2013specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib94","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin's lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib95","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"Lymphocyte-activation gene-3, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bneo.2026.100207_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1419118","article-title":"Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET\/CT-guided ABVD","volume":"14","author":"Cellini","year":"2024","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17474086.2024.2372325","article-title":"Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges","volume":"17","author":"Abeyakoon","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"1127","key":"10.1016\/j.bneo.2026.100207_bib98","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma\u2013an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.bneo.2026.100207_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1392653","article-title":"The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma","volume":"14","author":"Cashen","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib100","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjh.16844","article-title":"Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma","volume":"190","author":"Br\u00f6ckelmann","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s44313-025-00084-4","article-title":"Treatment of older patients with Hodgkin lymphoma","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib102","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib103","first-page":"877","article-title":"Prognostic impact of tumor-associated macrophages on survival is checkpoint dependent in classical Hodgkin lymphoma","volume":"12","author":"Karihtala","year":"2020","journal-title":"Cancers(Basel)"},{"key":"10.1016\/j.bneo.2026.100207_bib104","article-title":"Role and mechanisms of tumor-associated macrophages in hematological malignancies","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib106","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib107","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3324\/haematol.2019.243287","article-title":"Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP","volume":"106","author":"Jachimowicz","year":"2020","journal-title":"Haematol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100207_bib108","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib109","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-024-03108-6","article-title":"Hodgkin lymphoma and liquid biopsy: a story to be told","volume":"43","author":"Velasco-Suelto","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100207_bib110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.bneo.2026.100207_bib111","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.bneo.2026.100207_bib112","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3390\/cancers12123603","article-title":"Defining the inflammatory plasma proteome in pediatric Hodgkin lymphoma","volume":"12","author":"Agrusa","year":"2020","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.bneo.2026.100207_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89631","article-title":"Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients","volume":"1","author":"van Eijndhoven","year":"2016","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12121","article-title":"Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma","volume":"10","author":"Drees","year":"2021","journal-title":"J Extracell Vesicles"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib115","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.432","article-title":"Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma","volume":"3","author":"Drees","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.bneo.2026.100207_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115073","article-title":"Classic Hodgkin lymphoma: the LYSA pragmatic guidelines","volume":"213","author":"Rossi","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib117","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/oxfordjournals.annonc.a058662","article-title":"High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients","volume":"4","author":"Bierman","year":"1993","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100207_bib118","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V126.23.1978.1978","article-title":"Risk factors and a prognostic score for progression free survival after treatment with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (rrHL)","volume":"126","author":"Br\u00f6ckelmann","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100134","article-title":"Outcomes of immune checkpoint inhibitor rechallenge in relapsed\/refractory Hodgkin lymphoma","volume":"2","author":"Nishimura","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib121","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1080\/10428194.2016.1239263","article-title":"The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup\/>","volume":"58","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib122","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17719","article-title":"Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping","volume":"195","author":"Alcoceba","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100207_bib123","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","article-title":"The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA","volume":"5","author":"Buedts","year":"2021","journal-title":"Blood advances"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100207_bib124","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826","volume":"146","author":"Paczkowska","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.2021011941","article-title":"A gene expression\u2013based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma","volume":"139","author":"Johnston","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100207_bib126","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/bjh.16777","article-title":"Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma","volume":"190","author":"Calvente","year":"2020","journal-title":"Br J Haematol"},{"issue":"32","key":"10.1016\/j.bneo.2026.100207_bib127","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100207_bib128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood-2023-174139","article-title":"Multi-dimensional molecular and tumor-microenvironment analysis of classic Hodgkin lymphoma","volume":"142","author":"Aoki","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.seminhematol.2024.05.005","article-title":"Molecular biomarkers in classic Hodgkin lymphoma","volume":"61","author":"Kishida","year":"2024","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bneo.2026.100207_bib132","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40336-022-00481-0","article-title":"Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article","volume":"10","author":"Feres","year":"2022","journal-title":"Clin Transl Imaging"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib133","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100207_bib134","first-page":"1431","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.bneo.2026.100207_bib135","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib136","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1007\/s00330-022-09039-0","article-title":"Utility of pre-treatment FDG PET\/CT\u2013derived machine learning models for outcome prediction in classical Hodgkin lymphoma","volume":"32","author":"Frood","year":"2022","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib137","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.3025","article-title":"Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin lymphoma patients: a radio-genomic study","volume":"40","author":"Durmo","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib138","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cpf.12546","article-title":"Automated quantification of reference levels in liver and mediastinal blood pool for the Deauville therapy response classification using FDG-PET\/CT in Hodgkin and non-Hodgkin lymphomas","volume":"39","author":"Sadik","year":"2019","journal-title":"Clin Physiol Funct Imaging"},{"issue":"10","key":"10.1016\/j.bneo.2026.100207_bib139","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.3390\/jcm12103498","article-title":"Assessment of response to immunotherapy in patients with Hodgkin lymphoma: towards quantifying changes in tumor burden using FDG-PET\/CT","volume":"12","author":"Tutino","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100207_bib140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"Alvaro","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib141","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-023-05395-z","article-title":"Epigenetic alterations and advancement of lymphoma treatment","volume":"103","author":"Zhuang","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib142","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/leu.2011.194","article-title":"Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes","volume":"26","author":"Ammerpohl","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100207_bib143","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3390\/ijms25052457","article-title":"Pathogenic variants associated with epigenetic control and the NOTCH pathway are frequent in classic Hodgkin lymphoma","volume":"25","author":"Santisteban-Espejo","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib144","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semradonc.2020.07.003","article-title":"Theranostics: the role of quantitative nuclear medicine imaging","volume":"31","author":"K\u00f6nik","year":"2021","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100207_bib145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21571","article-title":"Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma","volume":"85","author":"Corazzelli","year":"2010","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100207_bib146","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.bneo.2026.100207_bib147","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100207_bib148","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","volume":"5","author":"Chang","year":"2024","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100207_bib149","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802600018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032802600018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:24:43Z","timestamp":1779294283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032802600018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S295032802600018X"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100207","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100207"}}